BioAdvance News Opsidio Portfolio News

Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases

By WebmasterSeptember 25, 2017November 1st, 2024No Comments

Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases

Previous PostMelior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes
Next PostOncora Medical raised $1.3 million to hire more tech staff